Entrada Therapeutics
TRDA
TRDA
97 hedge funds and large institutions have $481M invested in Entrada Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
14% more capital invested
Capital invested by funds: $423M → $481M (+$58.3M)
1.01% more ownership
Funds ownership: 79.9% → 80.91% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Holders
97
Holding in Top 10
4
Calls
$551K
Puts
$262K
Top Buyers
| 1 | +$2.59M | |
| 2 | +$2.06M | |
| 3 | +$1.53M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.36M |
Top Sellers
| 1 | -$7.99M | |
| 2 | -$5.34M | |
| 3 | -$1.37M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.36M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.16M |